Hikma appoints Rebecca Hall as CFO. Hikma stock gains 2.44 percent

Published on 10/06/2026 at 11:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was US$1.73 billion in first half of 2026, up 4.2 percent. Hikma stock costs EUR 19.33 on October 6, 2026 after EUR 18.87, plus 2.44 percent.

Fotorealistische sterile Pharma-Produktionslinie mit Injektionsfläschchen und Edelstahlanlagen — Hikma Pharmaceuticals PLC GB00B128J450 zeigt moderne Injektions-Produktionslinie in sterilem Pharmawerk mit Edelstahlanlagen, Illustration mit AI erstellt.

Hikma (ISIN GB00B0LCW083) was trading at EUR 19.33 at Lang & Schwarz on October 6, 2026 at 11:45 a.m. CEST, plus 2.44 percent versus the prior close of EUR 18.87. According to Hikma on September 24, 2026, Rebecca Hall will become chief financial officer and executive director in the first quarter of 2027. The appointment gives the leadership transition a defined successor while the stock trades higher in the current session.

Rebecca Hall starts in 2027

Hall will replace Khalid Nabilsi on the board, while Nabilsi is scheduled to leave the board on December 31, 2026 and continue as deputy chief executive for North America and Europe, the company said in the release dated September 24, 2026.

Hall joins from ViiV Healthcare, where she is senior vice president and chief financial officer. The transition keeps Areb Kurdi as acting CFO until Hall joins, making the first quarter of 2027 the next formal management milestone.

First-half revenue rose 4.20 percent

Simply Wall St reported that revenue reached US$1.73 billion in the first half of 2026, up 4.20 percent from the first half of 2025. Net income was US$223.0 million, down 6.30 percent year over year, while earnings per share fell to US$1.03 from US$1.08.

Hikma's investor-relations page dated August 6, 2026 said the company reiterated its full-year 2026 guidance. Branded revenue grew 15.00 percent in the first half, highlighting a stronger regional contribution even as the group-level net income comparison remained negative.

Jefferies keeps a Buy rating

MarketBeat reported that Jefferies reaffirmed its Buy rating on September 25, 2026 and set a GBp 2,025.00 price target. MarketBeat also listed six Buy ratings and a consensus target of GBp 2,085.83, giving the analyst backdrop a constructive tone despite the weaker first-half net income figure.

The LSE quote supplied by the finance data shows HIK at GBp 1,630.00 at 10:42 a.m. London time on October 6, 2026. Its 52-week range was GBp 1,187.00 to GBp 1,865.00, placing the exchange price below the yearly high while the euro quote remained positive on the day.

The euro quote and LSE context

At Lang & Schwarz, Hikma was trading at EUR 19.33 on October 6, 2026 at 11:45 a.m. CEST, up 2.44 percent versus the EUR 18.87 prior close. The combination of first-half revenue growth, a lower net income comparison and the planned CFO change leaves execution and margin delivery as the key company-specific measures for the next update. The further course of trading is shown by the continuously updated real-time quote of Hikma stock.